SG11201503612QA - Therapeutic agent for keratoconjunctive disorders - Google Patents

Therapeutic agent for keratoconjunctive disorders

Info

Publication number
SG11201503612QA
SG11201503612QA SG11201503612QA SG11201503612QA SG11201503612QA SG 11201503612Q A SG11201503612Q A SG 11201503612QA SG 11201503612Q A SG11201503612Q A SG 11201503612QA SG 11201503612Q A SG11201503612Q A SG 11201503612QA SG 11201503612Q A SG11201503612Q A SG 11201503612QA
Authority
SG
Singapore
Prior art keywords
therapeutic agent
keratoconjunctive disorders
keratoconjunctive
disorders
therapeutic
Prior art date
Application number
SG11201503612QA
Other languages
English (en)
Inventor
Kazuhiro Kimura
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50684334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503612Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of SG11201503612QA publication Critical patent/SG11201503612QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
SG11201503612QA 2012-11-08 2013-11-07 Therapeutic agent for keratoconjunctive disorders SG11201503612QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012246373 2012-11-08
PCT/JP2013/006563 WO2014073209A1 (ja) 2012-11-08 2013-11-07 角結膜障害の治療剤

Publications (1)

Publication Number Publication Date
SG11201503612QA true SG11201503612QA (en) 2015-06-29

Family

ID=50684334

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201704687YA SG10201704687YA (en) 2012-11-08 2013-11-07 Therapeutic agent for keratoconjunctive disorders
SG11201503612QA SG11201503612QA (en) 2012-11-08 2013-11-07 Therapeutic agent for keratoconjunctive disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201704687YA SG10201704687YA (en) 2012-11-08 2013-11-07 Therapeutic agent for keratoconjunctive disorders

Country Status (17)

Country Link
US (6) US9492431B2 (zh)
EP (1) EP2918290B1 (zh)
JP (3) JP6254529B2 (zh)
KR (1) KR102173932B1 (zh)
CN (2) CN109589324B (zh)
AU (2) AU2013342882B2 (zh)
BR (1) BR112015010428B1 (zh)
CA (1) CA2890424C (zh)
CL (2) CL2015001225A1 (zh)
ES (1) ES2834111T3 (zh)
HK (1) HK1219224A1 (zh)
MX (2) MX363111B (zh)
NZ (1) NZ708756A (zh)
RU (1) RU2659203C2 (zh)
SG (2) SG10201704687YA (zh)
WO (1) WO2014073209A1 (zh)
ZA (1) ZA201504065B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102173932B1 (ko) 2012-11-08 2020-11-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 각결막 장해의 치료제
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
MX362239B (es) 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.
IL263440B (en) 2016-06-08 2022-09-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
US10980778B2 (en) 2016-11-16 2021-04-20 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (MO)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT678086E (pt) 1993-01-11 2000-05-31 Ligand Pharm Inc Compostos com selectividade para receptores de retinoides x
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU784377B2 (en) 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis
BRPI0114344B8 (pt) 2000-10-02 2021-05-25 Hoffmann La Roche composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação
RU2299877C2 (ru) 2001-09-18 2007-05-27 Ф.Хоффманн-Ля Рош Аг Производные алкилмочевины, обладающие свойствами ретиноидных агонистов (i), фармацевтическая композиция и лекарственное средство
PL209697B1 (pl) 2001-09-18 2011-10-31 Hoffmann La Roche Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
EA200701998A1 (ru) 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции для инъекций наночастиц иммунодепрессивных соединений
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
EP1938815A1 (en) 2005-09-27 2008-07-02 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
AU2007233868A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
JP2009537540A (ja) 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ, インコーポレイテッド 化学療法および/または放射線療法の副作用を処置するためのrarアンタゴニストまたはrarインバースアゴニストの使用
JP5732182B2 (ja) * 2006-10-27 2015-06-10 エルパス・インコーポレイテッドLpath, Inc. 眼疾患と症状を処置するための組成物および方法
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) * 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
WO2012030919A2 (en) 2010-09-01 2012-03-08 Thomas Jefferson University Composition and method for muscle repair and regeneration
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
KR102173932B1 (ko) 2012-11-08 2020-11-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 각결막 장해의 치료제
MX362239B (es) 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.

Also Published As

Publication number Publication date
AU2018217197B2 (en) 2020-03-05
WO2014073209A1 (ja) 2014-05-15
US20150290172A1 (en) 2015-10-15
KR102173932B1 (ko) 2020-11-04
JP6744389B2 (ja) 2020-08-19
RU2659203C2 (ru) 2018-06-28
CL2018001915A1 (es) 2018-08-31
AU2013342882B2 (en) 2018-05-17
CA2890424A1 (en) 2014-05-15
BR112015010428A2 (pt) 2017-07-11
US11471440B2 (en) 2022-10-18
KR20150082326A (ko) 2015-07-15
ZA201504065B (en) 2016-11-30
US9750721B2 (en) 2017-09-05
EP2918290A1 (en) 2015-09-16
JPWO2014073209A1 (ja) 2016-09-08
CA2890424C (en) 2020-11-17
EP2918290B1 (en) 2020-09-02
CN109589324B (zh) 2022-06-14
JP6462836B2 (ja) 2019-01-30
ES2834111T3 (es) 2021-06-16
US10537556B2 (en) 2020-01-21
MX363111B (es) 2019-03-08
AU2018217197A1 (en) 2018-08-30
CN105188753A (zh) 2015-12-23
US20180000782A1 (en) 2018-01-04
MX2015005842A (es) 2016-01-20
NZ708756A (en) 2019-07-26
JP2019069992A (ja) 2019-05-09
CL2015001225A1 (es) 2016-03-04
US20170065562A1 (en) 2017-03-09
RU2015121628A (ru) 2016-12-27
CN105188753B (zh) 2018-12-18
CN109589324A (zh) 2019-04-09
US20190134002A1 (en) 2019-05-09
BR112015010428B1 (pt) 2020-04-22
SG10201704687YA (en) 2017-07-28
MX2019002526A (es) 2019-07-15
JP6254529B2 (ja) 2017-12-27
US10016395B2 (en) 2018-07-10
JP2018030887A (ja) 2018-03-01
US20200345695A1 (en) 2020-11-05
EP2918290A4 (en) 2016-05-18
AU2013342882A1 (en) 2015-06-11
HK1219224A1 (zh) 2017-03-31
US9492431B2 (en) 2016-11-15
US20230255937A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
HK1203963A1 (zh) 新型治療藥物
GB201212513D0 (en) Therapeutic agents
HK1206297A1 (zh) 用於聯合療法的藥物組合物
HK1206620A1 (zh) 血脂異常症治療劑
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
GB201217704D0 (en) Therapeutic agents
HK1201209A1 (zh) 糖尿病的治療藥
HK1219224A1 (zh) 角結膜病症的治療劑
PL2723330T3 (pl) Lek kombinowany zawierający środek naczynioskurczowy
EP2861242A4 (en) GLUTEN-MEDIATED DISEASES
GB201420971D0 (en) Therapeutic composition
EP2815763A4 (en) REMEDIES FOR INFLAMMATORY DISEASES
EP2914267A4 (en) TREATMENT OF DARM CONSTIPATION
EP2804853A4 (en) THERAPEUTIC USES
IL236873A0 (en) therapeutic compounds
ZA201405764B (en) Novel therapeutic agents
GB201223021D0 (en) Therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201213192D0 (en) Support for therapeutic
GB201211528D0 (en) Therapeutic apparatus
GB201202918D0 (en) Therapeutic device